Skin And Soft Tissue Infections - Pipeline Review, H1 2017

March 2017 | 40 pages | ID: SD2B3DD6FD9EN
Global Markets Direct

Abstracts

Skin And Soft Tissue Infections - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Skin And Soft Tissue Infections - Pipeline Review, H1 2017, provides an overview of the Skin And Soft Tissue Infections (Dermatology) pipeline landscape.

Skin and soft tissue infections are infections involving the layers of the skin and the soft tissues beneath it. Viruses, bacteria, and fungi generally cause skin and soft tissue infections by entering the body at a spot where a cut, scrape, bite, or other wound has broken the skin. Symptoms include swelling, warmth, and redness in a distinct area of skin, abscesses, furuncles and carbuncles. Risk factors include injury to the skin, radiation therapy, accumulation of fluid (edema) due to poor circulation, heart failure, liver disease, or past surgery to remove lymph nodes, being overweight and chronic skin conditions, such as eczema.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Skin And Soft Tissue Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Skin And Soft Tissue Infections (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Skin And Soft Tissue Infections (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Skin And Soft Tissue Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1, 3 and 1 respectively.

Skin And Soft Tissue Infections (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Skin And Soft Tissue Infections (Dermatology).
• The pipeline guide reviews pipeline therapeutics for Skin And Soft Tissue Infections (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Skin And Soft Tissue Infections (Dermatology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Skin And Soft Tissue Infections (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Skin And Soft Tissue Infections (Dermatology)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Skin And Soft Tissue Infections (Dermatology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Skin And Soft Tissue Infections (Dermatology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Skin And Soft Tissue Infections - Overview
Skin And Soft Tissue Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Skin And Soft Tissue Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Skin And Soft Tissue Infections - Companies Involved in Therapeutics Development
Atox Bio Ltd
CorMedix Inc
Takeda Pharmaceutical Company Ltd
Valevia UK Ltd
Wockhardt Ltd
Skin And Soft Tissue Infections - Drug Profiles
AB-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADEP-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alalevonadifloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceftaroline fosamil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRMD-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-7072 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Skin and Soft Tissue Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAL-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Skin And Soft Tissue Infections - Dormant Projects
Skin And Soft Tissue Infections - Product Development Milestones
Featured News & Press Releases
Nov 03, 2016: Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections
Jun 15, 2016: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of AB103 for Necrotizing Soft Tissue Infections
Dec 07, 2015: Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)
Sep 29, 2014: Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority
Aug 05, 2014: AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections
Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial
Sep 10, 2012: Atox Bio’s AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections
Oct 25, 2011: Atox Bio Receives Orphan Drug Designation For AB103 For Treatment Of Necrotizing Soft Tissue Infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Skin And Soft Tissue Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Skin And Soft Tissue Infections - Pipeline by Atox Bio Ltd, H1 2017
Skin And Soft Tissue Infections - Pipeline by CorMedix Inc, H1 2017
Skin And Soft Tissue Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Skin And Soft Tissue Infections - Pipeline by Valevia UK Ltd, H1 2017
Skin And Soft Tissue Infections - Pipeline by Wockhardt Ltd, H1 2017
Skin And Soft Tissue Infections - Dormant Projects, H1 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development for Skin And Soft Tissue Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017